Talis Biomedical (NASDAQ:TLIS) Shares Down 1.3%

Talis Biomedical Co. (NASDAQ:TLISGet Free Report) fell 1.3% on Thursday . The company traded as low as $8.88 and last traded at $9.03. 4,927 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 8,247 shares. The stock had previously closed at $9.15.

Talis Biomedical Price Performance

The firm has a market capitalization of $16.43 million, a price-to-earnings ratio of -0.29 and a beta of 1.69. The stock has a 50 day moving average price of $8.87 and a two-hundred day moving average price of $8.35.

Talis Biomedical (NASDAQ:TLISGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($7.15) earnings per share (EPS) for the quarter. Talis Biomedical had a negative return on equity of 75.40% and a negative net margin of 5,784.73%. The business had revenue of $0.07 million for the quarter.

Institutional Trading of Talis Biomedical

A hedge fund recently bought a new stake in Talis Biomedical stock. BML Capital Management LLC acquired a new stake in shares of Talis Biomedical Co. (NASDAQ:TLISFree Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 42,743 shares of the company’s stock, valued at approximately $318,000. BML Capital Management LLC owned about 2.35% of Talis Biomedical as of its most recent SEC filing. Institutional investors and hedge funds own 43.77% of the company’s stock.

About Talis Biomedical

(Get Free Report)

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Recommended Stories

Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.